Insiders Alnylam Pharmaceuticals, Inc.

Stocks

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 15/06/2026 BST			After hours 00:56:44
287.80 ^USD	+1.75%		288.90	+0.38%

06-10	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Insiders

05-27	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026	CI
03-05	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,227,698, According to a Recent SEC Filing	MT
02-18	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing	MT
02-18	Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing	MT
02-18	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing	MT
02-18	Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,008,766, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $3,475,157, According to a Recent SEC Filing	MT
01-14	Alnylam Pharmaceuticals Insider Sold Shares Worth $547,929, According to a Recent SEC Filing	MT
01-13	Alnylam Pharmaceuticals CEO on Development Goals, Profitability	MT
12-03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	CI
12-03	Alnylam Pharmaceuticals announces changes to board of directors	RE
03/10/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $2,692,062, According to a Recent SEC Filing	MT
03/10/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,103,451, According to a Recent SEC Filing	MT
03/10/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $635,126, According to a Recent SEC Filing	MT
03/10/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing	MT
02/09/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,557,649, According to a Recent SEC Filing	MT
19/08/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing	MT
19/08/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $3,163,346, According to a Recent SEC Filing	MT
19/08/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,030,727, According to a Recent SEC Filing	MT
19/08/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing	MT
19/08/25	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,299,746, According to a Recent SEC Filing	MT
18/06/25	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI